SCM
KRYS icon

Superstring Capital Management’s Krystal Biotech KRYS Stock Holding History

Superstring Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,086
Closed -$2M – 40
2023
Q4 		$2M Buy
+16,086
New +$1.78M 1.42% 21

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Superstring Capital Management's KRYS Position: Q1 2024 in Review

Superstring Capital Management sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 16,086 shares — an estimated $2M sold.

Superstring Capital Management first reported a position in KRYS in Q4 2023 and held it in 1 quarter. The position peaked at $2M in Q4 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Superstring Capital Management reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Superstring Capital Management sold 16,086 Krystal Biotech shares in Q1 2024, an estimated $2M.
  • Superstring Capital Management first reported a position in Krystal Biotech in Q4 2023 and held it in 1 quarter.
  • Superstring Capital Management's Krystal Biotech position peaked at $2M in Q4 2023.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Superstring Capital Management's 13F filing for Q1 2024, filed 15 May 2024.